U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

MedGen UID:
1706089
•Concept ID:
C5205066
•
Neoplastic Process
Synonyms: Refractory Diffuse Large B-Cell Lymphoma Non-GC/ABC; Refractory Diffuse Large B-Cell Lymphoma Non-Germinal Center/Activated B-Cell Type; Refractory Non-GC/ABC DLBCL

Definition

Diffuse large B-cell lymphoma activated B-cell type that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Professional guidelines

PubMed

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK
Am J Hematol 2021 May 1;96(5):617-629. Epub 2021 Mar 19 doi: 10.1002/ajh.26151. PMID: 33661537Free PMC Article
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler-Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F
Oncologist 2020 Feb;25(2):e321-e327. Epub 2019 Oct 16 doi: 10.1634/theoncologist.2019-0233. PMID: 32043764Free PMC Article
Novel disease targets and management approaches for diffuse large B-cell lymphoma.
Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA
Leuk Lymphoma 2010 Aug;51 Suppl 1(Suppl 1):1-10. doi: 10.3109/10428194.2010.500045. PMID: 20658952Free PMC Article

Recent clinical studies

Etiology

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol 2022 May;78(5):707-719. Epub 2022 Jan 21 doi: 10.1007/s00228-021-03253-3. PMID: 35061047
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK
Am J Hematol 2021 May 1;96(5):617-629. Epub 2021 Mar 19 doi: 10.1002/ajh.26151. PMID: 33661537Free PMC Article
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.
Sun F, Fang X, Wang X
Anticancer Agents Med Chem 2019;19(17):2047-2059. doi: 10.2174/1871520619666190925143216. PMID: 32009599
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Friedberg JW
Chin Clin Oncol 2015 Mar;4(1):9. doi: 10.3978/j.issn.2304-3865.2015.03.02. PMID: 25841716

Diagnosis

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.
Sun F, Fang X, Wang X
Anticancer Agents Med Chem 2019;19(17):2047-2059. doi: 10.2174/1871520619666190925143216. PMID: 32009599
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Haliotis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, Johnson NA
Clin Cancer Res 2016 May 1;22(9):2290-300. Epub 2015 Dec 8 doi: 10.1158/1078-0432.CCR-15-2123. PMID: 26647218
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Friedberg JW
Chin Clin Oncol 2015 Mar;4(1):9. doi: 10.3978/j.issn.2304-3865.2015.03.02. PMID: 25841716
Novel disease targets and management approaches for diffuse large B-cell lymphoma.
Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA
Leuk Lymphoma 2010 Aug;51 Suppl 1(Suppl 1):1-10. doi: 10.3109/10428194.2010.500045. PMID: 20658952Free PMC Article

Therapy

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK
Am J Hematol 2021 May 1;96(5):617-629. Epub 2021 Mar 19 doi: 10.1002/ajh.26151. PMID: 33661537Free PMC Article
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Harris LJ, Patel K, Martin M
Int J Mol Sci 2020 Nov 13;21(22) doi: 10.3390/ijms21228553. PMID: 33202794Free PMC Article
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M
Int J Mol Med 2020 Feb;45(2):279-297. Epub 2019 Dec 4 doi: 10.3892/ijmm.2019.4418. PMID: 31894255Free PMC Article
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Friedberg JW
Chin Clin Oncol 2015 Mar;4(1):9. doi: 10.3978/j.issn.2304-3865.2015.03.02. PMID: 25841716
GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J
Eur J Haematol 2008 Feb;80(2):127-32. Epub 2007 Nov 20 doi: 10.1111/j.1600-0609.2007.00996.x. PMID: 18005385

Prognosis

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.
Sun F, Fang X, Wang X
Anticancer Agents Med Chem 2019;19(17):2047-2059. doi: 10.2174/1871520619666190925143216. PMID: 32009599
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Friedberg JW
Chin Clin Oncol 2015 Mar;4(1):9. doi: 10.3978/j.issn.2304-3865.2015.03.02. PMID: 25841716
Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk 2011 Jun;11 Suppl 1:S87-90. Epub 2011 Apr 28 doi: 10.1016/j.clml.2011.03.029. PMID: 22035756
GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J
Eur J Haematol 2008 Feb;80(2):127-32. Epub 2007 Nov 20 doi: 10.1111/j.1600-0609.2007.00996.x. PMID: 18005385

Clinical prediction guides

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
Ofori K, Bhagat G, Rai AJ
Br J Clin Pharmacol 2021 Feb;87(2):284-294. Epub 2020 Nov 18 doi: 10.1111/bcp.14611. PMID: 33080045
Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM, Jang JY, Jeon YK, Paik JH
J Transl Med 2018 Jun 11;16(1):162. doi: 10.1186/s12967-018-1537-0. PMID: 29890998Free PMC Article
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
Friedberg JW
Chin Clin Oncol 2015 Mar;4(1):9. doi: 10.3978/j.issn.2304-3865.2015.03.02. PMID: 25841716
GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J
Eur J Haematol 2008 Feb;80(2):127-32. Epub 2007 Nov 20 doi: 10.1111/j.1600-0609.2007.00996.x. PMID: 18005385

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...